55,465 Shares in IDEAYA Biosciences, Inc. $IDYA Purchased by Lido Advisors LLC

Lido Advisors LLC bought a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the fourth quarter, Holdings Channel reports. The institutional investor bought 55,465 shares of the company’s stock, valued at approximately $1,913,000.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of IDEAYA Biosciences by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock worth $173,518,000 after purchasing an additional 97,116 shares in the last quarter. Baker BROS. Advisors LP increased its position in shares of IDEAYA Biosciences by 54.6% during the 3rd quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock worth $89,125,000 after purchasing an additional 1,156,716 shares in the last quarter. Fiera Capital Corp increased its position in shares of IDEAYA Biosciences by 20.0% during the 3rd quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock worth $50,011,000 after purchasing an additional 305,698 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of IDEAYA Biosciences by 43.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,770,866 shares of the company’s stock worth $61,219,000 after purchasing an additional 537,753 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of IDEAYA Biosciences by 4.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

Wall Street Analysts Forecast Growth

IDYA has been the subject of a number of recent analyst reports. Guggenheim increased their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. The Goldman Sachs Group increased their price objective on shares of IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, April 14th. Royal Bank Of Canada increased their price objective on shares of IDEAYA Biosciences from $49.00 to $53.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Wall Street Zen lowered shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Finally, Wells Fargo & Company increased their price objective on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. Fifteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.69.

IDEAYA Biosciences Trading Up 11.3%

Shares of NASDAQ IDYA opened at $31.48 on Tuesday. The firm has a market capitalization of $2.77 billion, a PE ratio of -19.68 and a beta of -0.04. IDEAYA Biosciences, Inc. has a 1 year low of $20.50 and a 1 year high of $39.28. The firm’s 50-day moving average is $30.18 and its 200-day moving average is $32.62.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The firm had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. The company’s revenue was down 39.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.82) earnings per share. As a group, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.27 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.